All News


All series


All All News

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.